Dr. Lloyd G. Goldfarb

Paul M. Hassoun, M.D., is professor of medicine at the Johns Hopkins University School of Medicine and the director of the pulmonary hypertension program at Johns Hopkins Hospital. He received his medical degree from the Faculté de Médecine Lariboisière-Saint Louis at the University of Paris, France, completed an internship and residency at Brigham and Women’s Hospital and a fellowship in Pulmonary and Critical Care Medicine at Massachusetts General Hospital, both at Harvard Medical School. He was on faculty in the pulmonary division at New England Medical Center/Tufts University School of Medicine (Tufts-NEMC) in Boston, MA, until 2002 when he joined the division of pulmonary and critical care medicine at Johns Hopkins University. Dr. Hassoun has served or currently serves on numerous American Thoracic Society (ATS) assemblies and committees, including the Pulmonary Circulation Long Range Planning Committee, the Pulmonary Circulation Program Committee (for which he served as chair for 2008-2009), the ATS Scientific Advisory Council, Pulmonary Circulation Leadership Committee, and the American College of Chest Physicians Vascular Steering Committee. He served as the ATS Pulmonary Circulation chair (2011-2012) and on the ATS Publications Policy Committee. He was recently elected president of the Pulmonary Vascular Research Institute (PVRI; 2018-2019). Dr. Hassoun has held numerous editorial activities including serving on the editorial board of the American Journal of Respiratory and Critical Medicine (2010 to present), CHEST (2006-2015) and the European Respiratory Review (2008-2015). He currently serves as associate editor of the European Respiratory Journal (2013-present) and has served as associate editor for the Journal of Clinical Investigation (2017-2022). Dr. Hassoun is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Pulmonary Hypertension, Systemic Sclerosis (SSc), Pulmonary Veno-Occlusive Disease, Cerebral Hypoxia, and Lung Transplant.

Dr. Kolb is a specialist in Pulmonary and Critical Care Medicine with special focus on pulmonary vascular disease and Critical Care Medicine. He is an expert in the diagnosis and management of all forms of chronic pulmonary hypertension, and has special interests in the chronic thromboembolic pulmonary hypertension, peri-operative and ICU management of pulmonary hypertension. He is an expert in the management of acute pulmonary embolism, leads the Johns Hopkins Pulmonary Embolism Response Team, and provides longitudinal ambulatory follow-up for patients after acute pulmonary embolism. He has extensive experience in the diagnosis and management of all forms of acute respiratory failure and other life-threatening conditions such as shock, gastrointestinal bleeding, pulmonary embolism, diabetic ketoacidosis and hyperosmolar states, and acute kidney and liver failure. Dr. Kolb is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Pulmonary Hypertension, Systemic Sclerosis (SSc), Pulmonary Veno-Occlusive Disease, Cerebral Hypoxia, and Lung Transplant.

Matthew Lammi, MD MSCR is an Associate Professor of Medicine and part of the Interstitial Lung Disease (ILD) Program. Dr. Lammi obtained his medical degree from Temple University School of Medicine and did his internal medicine, pulmonary, and critical care training at Temple University Hospital. He then joined the faculty at LSU in New Orleans, where he served as the Director of the Comprehensive Pulmonary Hypertension Center. He joined Johns Hopkins in 2023. He currently serves as the Associate Director of the Johns Hopkins Pulmonary Fibrosis Foundation Care Center and is the Associate Program Director for the Advanced Lung Disease Fellowship. His research focuses on the intersection between ILD and pulmonary hypertension, particularly in patients with systemic sclerosis. He is currently a co-Principal Investigator for a clinical trial of therapy for scleroderma associated pulmonary hypertension supported by the Department of Defense Peer Reviewed Medical Research Program. He is active in numerous societies and serves as the Chair of the Research Committee for the Pulmonary Hypertension Association. Dr. Lammi is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Pulmonary Hypertension, Sarcoidosis, Systemic Sclerosis (SSc), Interstitial Lung Disease, and Lung Transplant.